StreetInsider.com News Articles

Humana (HUM) PT Raised to $410 at BofA Securities

Mon, 20 Jul 2026 13:40:36 -0400

BofA Securities analyst Joanna Gajuk raised the price target on Humana (NYSE: HUM) to $410.00 (from $380.00) while maintaining a Neutral rating.

The analyst comments "We have been seeing trend slow down on a y/y basis through our trend tracker (see report here). On a same data point basis, trend slowed in May M/M: Inpatient decelerated -510bps m/m on a SS basis, followed by Physician (-480bps), and Outpatient (-20bps). Specialty Rx spend accelerated 40bps m/m, followed by Traditional Rx (260bps). With UNH and ELV both pointing to elevated but stable trend in commercial and Medicaid, the majority of this slowdown appears

Humana (HUM) PT Raised to $410 at BofA Securities

Mon, 20 Jul 2026 13:40:36 -0400

BofA Securities analyst Joanna Gajuk raised the price target on Humana (NYSE: HUM) to $410.00 (from $380.00) while maintaining a Neutral rating.

Humana (HUM) PT Raised to $350 at TD Cowen

Tue, 14 Jul 2026 08:42:49 -0400

TD Cowen analyst Ryan Langston raised the price target on Humana (NYSE: HUM) to $350.00 (from $211.00) while maintaining a rating.

Humana (HUM) PT Raised to $415 at Truist Securities

Tue, 14 Jul 2026 07:15:38 -0400

Truist Securities analyst David MacDonald raised the price target on Humana (NYSE: HUM) to $415.00 (from $320.00) while maintaining a Hold rating.

Humana (HUM) call put ratio 1.5 calls to 1 put as share price up 3.7%

Mon, 13 Jul 2026 14:26:03 -0400

Humana (NYSE: HUM) 30-day option implied volatility is at 58; compared to its 52-week range of 29 to 81. Call put ratio 1.5 calls to 1 put as share price up 3.7%.

Wells Fargo Upgrades Humana (HUM) to Overweight

Mon, 13 Jul 2026 05:11:14 -0400

Wells Fargo analyst Stephen Baxter upgraded Humana (NYSE: HUM) from Equal Weight to Overweight with a price target of $502.00 (from $227.00).

For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.

Shares of Humana closed at $392.22 yesterday.

Wells Fargo Upgrades Humana (HUM) to Overweight

Mon, 13 Jul 2026 05:11:14 -0400

Wells Fargo analyst Stephen Baxter upgraded Humana (NYSE: HUM) from Equal Weight to Overweight with a price target of $502.00 (from $227.00).

For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.

Shares of Humana closed at $392.22 yesterday.

Wells Fargo Upgrades Humana (HUM) to Overweight

Mon, 13 Jul 2026 05:11:14 -0400

Wells Fargo analyst Stephen Baxter upgraded Humana (NYSE: HUM) from Equal Weight to Overweight with a price target of $502.00 (from $227.00).

For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.

Shares of Humana closed at $392.22 yesterday.

Humana (HUM) PT Raised to $415 at RBC Capital

Thu, 09 Jul 2026 07:28:06 -0400

RBC Capital analyst Ben Hendrix raised the price target on Humana (NYSE: HUM) to $415.00 (from $246.00) while maintaining a Sector Perform rating.

Humana (HUM) PT Raised to $300 at Cantor Fitzgerald as Q/Q Enrollment Grows

Tue, 07 Jul 2026 07:30:49 -0400

Cantor Fitzgerald analyst Sarah James raised the price target on Humana (NYSE: HUM) to $300.00 (from $264.00) while maintaining a Neutral rating.

The analyst commented, "Our partial 2Q26 Medicaid enrollment data suggest the 2Q26 attrition environment is largely in-line with payor outlooks. CVS & HUM are trending most positive as enrollment grew Q/ Q, while MOH data are weakest, as enrollment losses Q/Q are tracking at a higher magnitude than peers in several states."

Humana (HUM) PT Raised to $300 at Cantor Fitzgerald as Q/Q Enrollment Grows

Tue, 07 Jul 2026 07:30:49 -0400

Cantor Fitzgerald analyst Sarah James raised the price target on Humana (NYSE: HUM) to $300.00 (from $264.00) while maintaining a Neutral rating.

Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald: Positive on Medicaid Exposure

Mon, 06 Jul 2026 06:52:05 -0400

Cantor Fitzgerald analyst Sarah James reiterated a Neutral rating and $264.00 price target on Humana (NYSE: HUM).

The analyst commented, "we're remaining positive on HUM's maturation into greater Medicaid exposure. In KY, where it saw its largest Q/Q losses, it was still on the stronger end of statewide performance & in LA it was a winner in the UNH contract termination. (=) KY, est. 13.0% Caid Rev / 1.4% Co. Rev: KY drove the highest enrollment losses Q/Q for HUM at 2% / 5K lives, but we don’t see this as consequential, as it's an improvement from the 4% losses in

Form 4 HUMANA INC For: Jun 30 Filed by: HILZINGER KURT J

Thu, 02 Jul 2026 20:55:00 -0400

si-local-file:///var/storage/secattach/20260702/26730247.html

Form 4 HUMANA INC For: Jun 30 Filed by: HILZINGER KURT J

Thu, 02 Jul 2026 20:55:00 -0400

si-local-file:///var/storage/secattach/20260702/26730247.html

The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants

Tue, 30 Jun 2026 08:00:00 -0400